Podcast: MDMA CEO Mark Leahey On Industry's Hot Topics
In an exclusive interview with Medtech Insight, MDMA's Mark Leahey – one of industry's top lobbyists – talked about the group's priorities over the past year and its continued work on hot-button issues, including medical device-tax repeal, reimbursement and implementing MDUFA IV provisions. He also discussed the imminent departure of US FDA Commissioner Scott Gottlieb and the recent federal government shutdown.
You may also be interested in...
Industry trade groups spend millions of dollars and walk thousands of steps in the halls of the US Congress each year to persuade legislators and their staff to support votes on device-tax repeal, Medicare payment reform, and other issues. Using lobbying reports downloaded by a public interest group, Medtech Insight has analyzed what industry spent and paid out to hire legislative experts to lobby Congress in the first half of 2019, and which topics they lobbied for the most.
The Medical Device Manufacturers Association (MDMA) on 10 July praised US Senate reintroduction of the STRONGER Patents Act, designed to strengthen the US patents systems by making it easier and less costly for patent-holders to enforce their patents, including those which are the intellectual property of device-makers. Mirror legislation was simultaneously proposed in the US House.
The tools include new laboratory methods, and computational models and simulations give the agency more capabilities to test and validate data in premarket submissions.